Zangmeister Cancer Center

Columbus, Ohio 43219

4 studies enrolling now · 20 studies all time

What they study most

Adenoid Cystic Carcinoma, Advanced Breast Cancer, Advanced Gastric Cancer, Advanced Solid Tumor, Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations, Breast Neoplasms, Cancer, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Colon Cancer, Colorectal Cancer, Endometrial Cancer

Studies at this site

• Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy — Recruiting now
• A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer — Recruiting now
• A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. — Recruiting now
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer — Recruiting now
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• Phase III Study of AK112 for NSCLC Patients — Running, not enrolling
• A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer — Completed
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC — Stopped early
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies — Completed
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression — Completed
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC — Running, not enrolling
• A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer — Stopped early
• A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer — Completed
• Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 — Stopped early
• A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen — Completed